Ceryvyn Therapeutics Ltd
OPT
Rankning i aktier
#31781
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Aktiekurs
$0.00846342
Senast synkroniserad: 2026-07-27
Marknadsvärde
$11.27M
Förändring (1 dag)
0.00%
Förändring (1 år)
-99.75%
Land
AU
Handel Ceryvyn Therapeutics Ltd (OPT)
Kategori
Healthcare
Aktiekurshistorik för Ceryvyn Therapeutics Ltd (OPT)
Högsta slutkurs: $3.41 den 2025-04-01
Lägsta slutkurs: $13.17 den 2020-10-01
Lägsta slutkurs: $13.17 den 2020-10-01
Aktiekurshistorik för Ceryvyn Therapeutics Ltd från 2020 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2025 | -4.06% |
| 2024 | 37.44% |
| 2023 | -49.05% |
| 2022 | -27.97% |
| 2021 | -41.46% |
| 2020 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.90 | -4.43% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
